CSL Limited
CSL
株式のランク
#362
CSL Limited operates as a global biopharmaceutical company, engaged in the... CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
株価
$138.58
時価総額
$66.50B
変化（1日）
0.72%
変化（1年）
-2.29%
国
AU
取引 CSL Limited (CSL)
カテゴリー
Healthcare
CSL Limited（CSL）の利益
Jun 2026 時点の利益 TTM: $-4.02B
CSL Limited の最新の財務報告によると、同社の現在の利益は $-4.02B です。2024 年には $3.38B の利益を上げ、これは 2023 年の利益 $2.66B と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
CSL Limited の利益の推移（2000 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $-4.02B | -207.85% |
| 2025 | $3.72B | 10.34% |
| 2024 | $3.38B | 26.74% |
| 2023 | $2.66B | -4.19% |
| 2022 | $2.78B | -6.80% |
| 2021 | $2.98B | 15.92% |
| 2020 | $2.57B | 9.89% |
| 2019 | $2.34B | 2.63% |
| 2018 | $2.28B | 35.00% |
| 2017 | $1.69B | 8.61% |
| 2016 | $1.56B | -9.22% |
| 2015 | $1.71B | 6.84% |
| 2014 | $1.60B | 19.64% |
| 2013 | $1.34B | 5.36% |
| 2012 | $1.27B | -7.31% |
| 2011 | $1.37B | 38.29% |
| 2010 | $992.87M | 11.00% |
| 2009 | $894.45M | 2.37% |
| 2008 | $873.74M | 56.73% |
| 2007 | $557.47M | 493.43% |
| 2006 | $93.94M | -74.77% |
| 2005 | $372.39M | 201.20% |
| 2004 | $123.64M | 168.99% |
| 2003 | $45.96M | -7.38% |
| 2002 | $49.63M | -8.38% |
| 2001 | $54.17M | 88.04% |
| 2000 | $28.81M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | -231.34% |
US
|
|
| $-3.09B | -23.14% |
US
|
|
| - | - |
CH
|
|
| $1.95B | -148.57% |
NL
|
|
| $3.01B | -174.84% |
BE
|
